Quitting My Job And Living In Costa Rica

http://www.happierthanabillionaire.com/

Sent from my iPhone

abstract: Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers (serous/mucinous)

Blogger's Note: the connection between KRAS mutations/mucinous may be due to GI (particularly colorectal cancer eg. common denominator = KRAS mutation/mucinous cell type), see also mucinous article - to be posted subsequent to this item

BACKGROUND:
This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.

PATIENTS AND METHODS:

A total of 126 patients were included in this study. KRAS mutations and CFDNA were detected by means of the PCR-restriction fragment length polymorphism (PCR-RFLP) and enriched by the PCR-RFLP method. Enzyme-linked immunosorbent assay was used to analyze plasma p53-Ab.

RESULTS:

KRAS mutations were detected in 27 (21.4%) of examined tumors. The frequency of KRAS mutations was especially high in mucinous cancers (P < 0.001). CFDNA and p53-Ab were frequently detected in patients with serous cancers in high grade (P < 0.001). The overall survival rate was significantly lower for patients with serous tumors and CFDNA and p53-Ab-positive than negative tumors (P = 0.022 and P < 0.001, respectively). In mucinous ovarian cancer, a worse overall survival was correlated with the KRAS mutations (P = 0.03).

CONCLUSIONS:

The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression.

abstract: Mucinous tumor of low malignant potential ("borderline" or "atypical proliferative" tumor) of the ovary: a study of 171 cases with the asses

Abstract

Mucinous tumors of the ovary are a continuing source of controversy in the field of gynecologic pathology. We examined a series of 171 intestinal-type mucinous tumors of low malignant potential ("borderline" or "atypical proliferative" tumors) to clarify the clinical significance of intraepithelial carcinoma (IECA) and microinvasion (area ≤ 10 mm²). The diagnosis of IECA was based on the presence of marked nuclear atypia (grade 3). Stromal microinvasion was classified as low grade and high grade (with nuclear grade 3). IECA was observed in 67 of 171 cases (39.2%). Microinvasion was identified in 31 (18.1%) cases, low grade in 22 (12.9%) cases, and high grade in 9 (5.3%) cases. Follow-up status was known in 144 cases and tumor recurrence was observed in 6 patients (4.2%). The risk factors for recurrence included International Federation of Gynecology and Obstetrics stage ≥ IC (P=0.002), microinvasion (P=0.013), age less than 45 years (P=0.032), and IECA (P=0.042). The amount of IECA ≥ 10% was also associated with the risk of recurrence (P=0.007). Among tumors with microinvasion, there was no significant association between the clinicopathologic variables and recurrence. When considering tumors with stage ≥ IC, tumor recurrence was significantly associated with IECA ≥ 10% (P=0.031) and age less than 45 years (P=0.047). It is important that mucinous tumors of low malignant potential should be staged and be optimally sampled for pathologic examination to document the status of the external surface or peritoneal involvement and to identify the worst degree of epithelial proliferation. Tumor stage ≥ IC, IECA ≥ 10%, microinvasion, and age less than 45 years were the features that were associated with tumor recurrence.
The study results also support the use of nuclear grade 3 as the sole criterion of IECA.

abstract: (small study) Cancer-Related Sources of Stress for Children With Cancer and Their Parents

Note: note differences in participation between mothers and fathers (n); abstract only info does not detail this variance


Objectives
The current study examines reports and correlates of cancer-specific stressors in children with cancer and their parents. Measures
Mothers (n = 191) and fathers (n = 95) reported on their own and their child’s stressors, general perceived stress, and posttraumatic stress symptoms. Children (n = 106) completed self-reports of their own stressors and posttraumatic stress symptoms.

Cancers | Free Full-Text | Assessment of the Evolution of Cancer Treatment Therapies

Note: numerous references to ovarian cancer

Conclusions

This review has tried to summarize the history and evolution of the most common types of cancer

treatments available today, but also new therapies under study in the last years. In addition to surgery,

chemotherapy, radiation therapy, hyperthermia, photodynamic therapy or immunotherapy, new

therapies are now at different stages of development trying to decrease drug toxicity in health tissues

and increase efficacy by targeting tumor angiogenesis, by exploring cell and gene therapy, or by using

new nanostructures for diagnosis or therapeutic purposes. Nanotechnology is offering new products,

which either used alone, due to their intrinsic properties, or in combination with other biomolecules

(anti-tumoral drugs, folic acid, albumin, antibodies, aptamers) could be used to target cancer cells.

However, the history tells us that the fight against cancer is not an easy task. Many types of cancers

are able to resist to conventional therapies, and different combinations of drugs and therapies

(e.g., surgery together with radiotherapy and chemotherapy) are usually the only way to destroy

tumoral cells. This may be also true for the new therapies arriving now to the clinic. Much more

studies are required but these new ways of treatment are opening doors to hope for many patients

waiting for a successful therapy

AHRQ: Su medicamento: Infórmese. Evite riesgos. (Incluye tarjeta de bolsillo) Spanish/English

AHRQ Releases a Spanish-Language Tool to Help Consumers Reduce Medication Errors

AHRQ has released a revised Spanish-language medication safety booklet, “Su medicamento: Infórmese. Evite riesgos” (“Your Medicine: Be Smart. Be Safe.”) to help Spanish-speaking patients learn more about how to take medicines safely. The booklet includes a detachable, wallet-size card that can help patients keep track of medicines they are taking, including vitamins and herbal and other dietary supplements. Select to download a copy of the guide in Spanish. Print copies are available by sending an e-mail to AHRQPubs@ahrq.hhs.gov. The guide is also available in English.

a request: survivors stories for interviews (per Women's Oncology Research & Dialogue Newsletter)

WORD is looking for new women to be interviewed about their journey and fight against gynecologic cancers.  If you would be willing to work with us - please contact us soon!